AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC trimmed its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 9.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,528,614 shares of the medical device company's stock after selling 262,144 shares during the period. Champlain Investment Partners LLC owned 5.19% of AtriCure worth $77,274,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Canada Pension Plan Investment Board grew its holdings in AtriCure by 756.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 35,100 shares of the medical device company's stock valued at $1,073,000 after buying an additional 31,000 shares in the last quarter. Marshall Wace LLP boosted its position in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after acquiring an additional 167,476 shares during the last quarter. Advisors Capital Management LLC grew its holdings in shares of AtriCure by 8.0% in the fourth quarter. Advisors Capital Management LLC now owns 96,082 shares of the medical device company's stock valued at $2,936,000 after purchasing an additional 7,130 shares in the last quarter. Kennedy Capital Management LLC increased its position in AtriCure by 29.8% in the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after purchasing an additional 172,648 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in AtriCure during the fourth quarter valued at $3,716,000. 99.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ATRC has been the topic of a number of research reports. Oppenheimer boosted their target price on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Stifel Nicolaus boosted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Canaccord Genuity Group cut their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday, March 28th. Finally, JPMorgan Chase & Co. lowered their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $49.44.

Insider Buying and Selling

In other news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is currently owned by insiders.

AtriCure Trading Up 2.0 %

Shares of AtriCure stock traded up $0.64 on Tuesday, hitting $32.38. 166,587 shares of the company traded hands, compared to its average volume of 653,792. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.58 billion, a PE ratio of -34.17 and a beta of 1.65. The stock's 50 day moving average price is $34.88 and its 200-day moving average price is $34.49. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.